Morningstar - Golden Agri-Resources Ltd (E5H) Golden Agri Delivers Disappointing Q4 Results on Exceptional Items; Increasing FVE to SGD 0.35

Report

Morningstar

Chokwai Lee, CFA

EUR 101.80 For Business Accounts Only

Golden Agri Delivers Disappointing Q4 Results on Exceptional Items; Increasing FVE to SGD 0.35

No-moat Golden Agri delivered fourth-quarter results that fell short of our expectations, mainly due to an impairment loss in China amounting to USD 34 million and lower-than-expected tax credits. Nonetheless, Golden Agriâ€™s operating figures beat our expectations with higher-than-expected output and selling prices for palm products, while the companyâ€™s full-year revenue and EBITDA for 2016 saw year-over-year growth of 11.0% and 6.0%, respectively. We have reduced our earnings forecasts for 2017 ...

27/02/2017 12 EN

Underlying

Golden Agri-Resources Ltd

Golden Agri-Resources is an investment holding company. Co. and its subsidiaries have four reportable operating segments: Plantation and Palm Oil Mills, which comprises the products from the upstream business; Palm and Laurics, which comprises the processing and merchandising of palm based products, i.e. bulk and branded as well as oleochemicals; Oilseeds, which comprises the processing and merchandising of oilseeds based products, i.e. bulk and branded; and Others, which comprises the production and distribution of food and consumer products in China and Indonesia.

See profile

MU0117U00026 Singapore Exchange Singapore

Provider

Morningstar

Morningstar, Inc. is a leading provider of independent investment research in North America, Europe, Australia, and Asia. The company offer an extensive line of products and services for individual investors, financial advisors, asset managers, and retirement plan providers and sponsors.

Morningstar provides data on approximately 530,000 investment offerings, including stocks, mutual funds, and similar vehicles, along with real-time global market data on more than 18 million equities, indexes, futures, options, commodities, and precious metals, in addition to foreign exchange and Treasury markets. Morningstar also offers investment management services through its investment advisory subsidiaries and had approximately $185 billion in assets under advisement and management as of June 30, 2016.

We have operations in 27 countries.

See profile

Analysts

Chokwai Lee, CFA

Other Reports on these Companies

SmartInsider

Golden Agri Resources: 1 director

A director at Golden Agri Resources bought 250,000 shares at 0.235SGD and the significance rating of the trade was 60/100. Is that information sufficient for you to make an investment decision? This report gives details of those trades and adds context and analysis to them such that you can judge whether these trading decisions are ones worth following. Included in the report is a detailed share price chart which plots discretionary trades by all the company's directors over the last two years clearly showing Close periods where trading activity is restricted under listing rules. The names...

Free Trial

January 11, 2025 January 11, 2025 1 EN

UOB

Singapore Strategy - To Indonesia Via Singapore

Indonesia’s economic performance has been strong on a ytd basis with the rupiah outperforming its regional peers, thus resulting in the JCI outperforming its peers in US dollar terms. We highlight various sectors and stocks listed on the SGX that could benefit from this strength with our top picks being Delfi, Marco Polo Marine and Raffles Medical.

June 8, 2023 June 8, 2023 1 EN

TheScreener

Thanks to a better fundamental star rating, GOLDEN AGRI-RESOURCES sees an upgrade to Neutral

The independent financial analyst theScreener just awarded an improved star rating to GOLDEN AGRI-RESOURCES (SG), active in the Farming & Fishing industry. As regards its fundamental valuation, the title receives an improved star rating and now shows 2 out of 4 possible stars. With regard to its market behaviour, it remains unchanged and can be qualified as moderately risky. theScreener considers that these elements allow slightly upgrading its rating to Neutral. As of the analysis date February 8, 2022, the closing price was SGD 0.28 and its expected value was estimated at SGD 0.25.

Free Trial

February 9, 2022 February 9, 2022 1 EN

Business as Usual for No-Moat Lonza; Specialty Ingredients Carve-Out on Track for 2020

Contract manufacturer Lonza reported solid half-year results, with over CHF 2.9 billion in total sales year to date, up about 6.4% from last year and boosted by foreign exchange tailwinds. Core EBITDA margin expanded 30 basis points from last year to about 27.8%, helped slightly by new accounting standards. Management indicated that it continues to expect mid- to high-single-digit sales growth in 2019. We are maintaining our fair value estimate of CHF 210 per share and our no-moat rating. The ph...

EUR 100.00

July 25, 2019 July 25, 2019 13 EN

Damien Conover

Damien Conover

Astra Posts Solid 2Q, Driven by Strong Cancer Drug Sales and Moving Away From One-Time Divestments

We don't expect any major changes to our AstraZeneca fair value estimate following second-quarter results that largely fell in line with our expectations and slightly ahead of consensus expectations. Overall, the company is posting leading Big Pharma sales growth with total sales up 18% operationally year over year, led by impressive cancer drug sales growth of 57%. Astra's ability to continue to bring next generation drugs to the market that address unmet medical need (especially in oncology) s...

EUR 100.00

July 25, 2019 July 25, 2019 14 EN

Damien Conover

Damien Conover

Astra Posts Solid 2Q, Driven by Strong Cancer Drug Sales and Moving Away From One-Time Divestments

EUR 100.00

July 25, 2019 July 25, 2019 14 EN

Sign-up for free to access full reports immediately

Email Address*

Choose Password* ( 6 or more characters )

Due to regulatory restrictions regarding the distribution of financial research, this report is restricted to a specific region or investor type. Get access to exclusive reports by answering the questions below.

Select your country*

Get financial insights straight to your inbox

By clicking "register" you accept the Terms and Conditions & Privacy Policy

Already on ResearchPool?

Almost there...

Are you a professional investor?

Select your country

REGISTER

Create a free ResearchPool account to access full reports, get a personalised dashboard and follow providers or companies

In order to access this report please create an account.

LOGIN

Golden Agri Delivers Disappointing Q4 Results on Exceptional Items; Increasing FVE to SGD 0.35

Golden Agri Resources: 1 director

Singapore Strategy - To Indonesia Via Singapore

Thanks to a better fundamental star rating, GOLDEN AGRI-RESOURCES sees an upgrade to Neutral

Business as Usual for No-Moat Lonza; Specialty Ingredients Carve-Out on Track for 2020

Astra Posts Solid 2Q, Driven by Strong Cancer Drug Sales and Moving Away From One-Time Divestments

Astra Posts Solid 2Q, Driven by Strong Cancer Drug Sales and Moving Away From One-Time Divestments

Create a free ResearchPool account to access full reports, get a personalised dashboard and follow providers or companies

Sign-up for free to access full reports immediately

ResearchPool Subscriptions

Get the most out of your insights

Why subscribe?

How to subscribe

ResearchPool Subscriptions

This report is only available to subscribers

Why subscribe?

How to subscribe